Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 6/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906512 | 0.86 | RXRB (0.51) | HSPB1RXRBMAPK14 | |
| SCHEMBL21906515 | 0.86 | RXRB (0.50) | RXRB | |
| SCHEMBL21906319 | 0.86 | RXRB (0.51) | HSPB1RXRBMAPK14 | |
| SCHEMBL21906693 | 0.85 | MEN1 (0.53) | RXRBMAP4K4KDM4E | |
| SCHEMBL21906532 | 0.80 | RXRB (0.45) | HSPB1RXRBMAP4K4TRPA1 | |
| SCHEMBL23361483 | 0.79 | HSPB1 (0.56) | HSPB1RXRBMAP4K4MAPK14TRPA1 | |
| SCHEMBL29874073 | 0.79 | HSPB1 (0.56) | HSPB1RXRBMAP4K4MAPK14TRPA1 | |
| SCHEMBL21906692 | 0.78 | L3MBTL1 (0.50) | HSPB1RXRBKDM4E | |
| SCHEMBL21906531 | 0.78 | RXRB (0.46) | HSPB1RXRBMAPK14TRPA1 | |
| SCHEMBL24298069 | 0.77 | HSPB1 (0.52) | HSPB1MAP4K4MAPK14TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867244-B1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2023-01-18 | — | — | EP | disclosed |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2020079039-A1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121691-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | HSPB1 3171/4885RXRB 595/4885MAP4K4 593/4885 |
| US-20210393644-A1 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | HSPB1 3171/4885RXRB 595/4885MAP4K4 593/4885 |
| US-11166958-B2 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2A, GRIN2C, GRIN3A | HSPB1 3171/4885RXRB 595/4885MAP4K4 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.